New Stock News | Harmoni Pharmaceuticals files again with the Hong Kong Stock Exchange
According to the disclosure made by the Hong Kong Stock Exchange on June 8th, Ganzhou Hemei Pharmaceutical Co., Ltd. (referred to as Hemei Pharmaceutical) has submitted its application to the Main Board of the Hong Kong Stock Exchange, with Guotou Securities International as its exclusive sponsor.
According to the Hong Kong Stock Exchange disclosure on June 8th, Ganzhou Hemei Pharmaceutical Co., Ltd. (referred to as Hemei Pharmaceutical) has submitted an application to the main board of the Hong Kong Stock Exchange, with Guotou Securities International as its exclusive sponsor. The company had previously submitted an application to the Hong Kong Stock Exchange on December 1, 2025. The prospectus disclosed that Hemei Pharmaceutical is a biopharmaceutical company dedicated to discovering and developing small molecule drugs for autoimmune diseases and tumors. As of the last practicable date, its pipeline products include seven small molecule drug candidates (including two core products Mufemilast and Hemay022). Mufemilast has been approved for NDA in China.
Related Articles
Cipher Digital (CIFR.US) intends to issue $810 million junk bonds for the construction of Amazon.com, Inc. (AMZN.US) AI data center project.
US Stock Market Move | EHang Holdings Ltd. Sponsored ADR Class A (EH.US) surged more than 11%, spending $30 million to repurchase shares.
Italian technology and software giant Bending Spoons (BSP.US) applies for IPO in the United States, with a rumored target valuation of up to $22 billion.
Cipher Digital (CIFR.US) intends to issue $810 million junk bonds for the construction of Amazon.com, Inc. (AMZN.US) AI data center project.
US Stock Market Move | EHang Holdings Ltd. Sponsored ADR Class A (EH.US) surged more than 11%, spending $30 million to repurchase shares.
Italian technology and software giant Bending Spoons (BSP.US) applies for IPO in the United States, with a rumored target valuation of up to $22 billion.
